LeMaitre Vascular (LMAT)
(Real Time Quote from BATS)
$62.45 USD
-1.58 (-2.47%)
Updated Apr 25, 2024 10:50 AM ET
1-Strong Buy of 5 1
D Value D Growth D Momentum D VGM
LeMaitre Vascular (LMAT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$67.17 | $75.00 | $59.00 | 4.90% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for LeMaitre Vascular comes to $67.17. The forecasts range from a low of $59.00 to a high of $75.00. The average price target represents an increase of 4.9% from the last closing price of $64.03.
Analyst Price Targets (6 )
Broker Rating
LeMaitre Vascular currently has an average brokerage recommendation (ABR) of 1.86 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.86 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, four are Strong Buy, representing 57.14% of all recommendations. A month ago, Strong Buy represented 57.14%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 3 | 3 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.86 | 1.86 | 1.86 | 1.86 | 1.67 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
2/28/2024 | Barrington Research | Michael J Petusky | Strong Buy | Strong Buy |
2/6/2024 | KeyBanc Capital Markets | Brett Fishbin | Hold | Hold |
10/23/2023 | JMP Securities | David L Turkaly | Not Available | Strong Buy |
8/2/2023 | Lake Street Capital Markets | Brooks G O'Neil | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.86 |
ABR (Last week) | 1.86 |
# of Recs in ABR | 7 |
Average Target Price | $67.17 |
LT Growth Rate | 14.00% |
Industry | Medical - Products |
Industry Rank by ABR | 150 of 252 |
Current Quarter EPS Est: | 0.39 |